Crossmark

Comparative effectiveness and safety of aztreonam-avibactam or ceftazidime-avibactam plus aztreonam versus best available therapy for severe gram-negative infections: a systematic review, meta-analysis, and trial sequential analysis

Crossref DOI link: https://doi.org/10.1007/s10096-026-05482-9

Published Online: 2026-03-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Changqin

Mao, Wenchao

Zhao, Changyun

Lu, Difan

Hu, Weihang

Xiong, Jianqiang
Funding

Funding for this research was provided by:

Medical Science and Technology Project of Zhejiang Province (2020KY007, 2022KY477 and 2022KY001)
License Information

Text and Data Mining valid from 2026-03-20

Version of Record valid from 2026-03-20
More Information

Article History

Received: 21 December 2025

Accepted: 16 March 2026

First Online: 20 March 2026

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below